ANTABIO

About

Antabio is a clinical-stage biopharmaceutical company dedicated to developing innovative antibacterials and resistance-breakers aimed at combating drug-resistant pathogens. The company focuses on creating stand-alone inhibitors of bacterial metalloenzymes to restore antibiotic effectiveness against critical Gram-negative pathogens, including carbapenem-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. Founded to address the challenge of drug-resistant infections, Antabio has achieved significant milestones, including raising €25 million in Series B financing in 2023 to advance its lead candidate, MEM-ANT3310, through Phase 2 trials. The company’s pipeline includes several promising products, such as ANT3273, an elastase inhibitor targeting *P. aeruginosa* biofilms, and the PEi Program, which focuses on inhaled therapies for cystic fibrosis patients. Antabio's research is supported by partnerships with organizations like the AMR Action Fund and the Wellcome Trust, reflecting its commitment to addressing urgent healthcare needs.